Ohio State and Moffitt Form World’s Largest Cancer Research Collaboration for Big Data; More Than 100,000 Patients Already Participating

Two of North America’s leading cancer centers, Moffitt Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), recently announced what is likely the largest collaboration of its kind to accelerate discoveries in cancer research.

MedPage Today and CollabRx Introduce CancerRx, A New Decision Support Mobile Application for Oncology

MedPage Today, a property of Everyday Health, Inc. (NYSE: EVDY), and CollabRx, Inc. (NASDAQ: CLRX) recently announced the introduction of a new physician resource, CancerRx,™ an IOS application designed to help oncologists and pathologists navigate the complex landscape of oncology therapeutic options.

SAP Announces Strategic Alliances to Drive Forward Genomic Research

SAP AG recently announced a strategic collaboration with Stanford School of Medicine to research the contribution of genetics, environmental exposures, behavior and other factors to disease susceptibility using the power of the SAP HANA platform. The company also announced its participation in the Global Alliance for Genomics and Health, a council of industry leaders working toward accelerating worldwide efforts to responsibly share and analyze large amounts of genomic and clinical data.

QIAGEN Receives FDA Approval of therascreen KRAS RGQ PCR Kit Paired with Second Colorectal Cancer Drug

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced that its therascreen® KRAS RGQ PCR Kit (therascreen KRAS test) has received U.S. Food and Drug Administration (FDA) approval to guide the treatment of metastatic colorectal cancer patients with Amgen’s Vectibix® (panitumumab). This marks the third FDA approval of a companion diagnostic from QIAGEN that has been paired with a novel medicine.

Immucor PreciseType HEA Test Becomes the First-Ever FDA-Approved Diagnostic for Molecular Typing of Donor and Recipient Red Blood Cells for Blood Transfusions

Immucor, Inc., a global leader in transfusion and transplantation diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company’s PreciseType HEA test. The PreciseType HEA test is the first FDA-approved molecular assay designed to provide clinicians and blood banks with the detailed genetic matching information they need to reduce the risk of alloimmunization and serious hemolytic reactions, which is especially problematic for patients receiving frequent blood transfusions. These include people with genetic disorders, such as sickle cell disease, thalassemia, and patients with certain kinds of cancer.